Nuvation Bio (NUVB) Projected to Release Quarterly Earnings on Wednesday

Nuvation Bio (NYSE:NUVB) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Nuvation Bio to announce earnings of ($0.1236) per share and revenue of $34.39 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $31.69 million for the quarter, compared to analyst estimates of $27.03 million. On average, analysts expect Nuvation Bio to post ($0.34) EPS for the current fiscal year and ($0.17) EPS for the next fiscal year.

Nuvation Bio Price Performance

NUVB opened at $4.54 on Wednesday. The firm has a market cap of $1.59 billion, a P/E ratio of -10.31 and a beta of 1.61. Nuvation Bio has a 1-year low of $3.92 and a 1-year high of $9.75. The company has a 50 day simple moving average of $5.77 and a two-hundred day simple moving average of $5.46.

Insider Buying and Selling

In related news, insider Gary Hattersley sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total value of $709,000.00. Following the transaction, the insider directly owned 100,000 shares of the company’s stock, valued at approximately $709,000. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 30.11% of the company’s stock.

Wall Street Analyst Weigh In

NUVB has been the topic of several recent analyst reports. B. Riley Financial restated a “buy” rating on shares of Nuvation Bio in a research report on Friday, August 7th. Cantor Fitzgerald initiated coverage on shares of Nuvation Bio in a report on Friday, August 21st. They issued an “overweight” rating for the company. Citizens Jmp reaffirmed a “market outperform” rating and issued a $10.00 target price on shares of Nuvation Bio in a report on Wednesday, September 16th. Zacks Research upgraded Nuvation Bio from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Finally, JPMorgan Chase & Co. assumed coverage on Nuvation Bio in a report on Tuesday, August 18th. They set an “overweight” rating and a $13.00 price target on the stock. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $13.22.

Nuvation Bio Company Profile

Nuvation Bio, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors.

Nuvation Bio’s lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments.